188 results on '"Mizukami, Takuro"'
Search Results
2. Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022
3. Transdifferentiation of cervical squamous cell carcinoma with ERBB2 amplification to adenocarcinoma: whole genome sequence analysis and successful control by anti-HER2 therapy
4. An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer
5. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy
6. Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers
7. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
8. Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations.
9. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID)
10. Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer
11. P8-10 WGS analysis of Erbb2-amplified cervical cancer with two simultaneous histologic types: Transdifferentiation hypothesis
12. P63-5 Cases of atypical femur fractures; the rare adverse events requiring the multidisciplinary team decision-making
13. P3-5 DLBCL developed during the immune checkpoint inhibitor therapy in a patient with advanced gastric cancer
14. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
15. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy
16. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan
17. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives
18. Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy
19. Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer
20. Data from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
21. Supplementary Table Legends from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
22. Supplementary Table 1 from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
23. Supplementary Table 2 from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
24. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
25. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
26. O1-6 REVIVE study: An observational study in chemotherapy (CTx) after nivolumab (NIVO) for advanced gastric cancer (AGC)
27. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling
28. Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies
29. The utility of G8 screening for clinical practice of chemotherapy in older patients with gastrointestinal cancer
30. A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
31. REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).
32. Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.
33. Additional file 7 of Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
34. Additional file 6 of Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
35. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study
36. An Exploration of Trifluridine/Tipiracil in Combination with Irinotecan in Patients with Pretreated Advanced Gastric Cancer
37. Decision Making for Anti-VEGF Inhibitor Continuation: Dip Stick? or Urine Protein/Creatinine Ratio? (VERSiON UP Study)
38. Prediction of esophagogastric varices associated with oxaliplatin administration
39. Clinicopathological and Genetic Differences Between Low-Grade and High-Grade Colorectal Mucinous Adenocarcinomas
40. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer
41. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition
42. MO1-2 Geriatric assessment and clinical outcomes for elderly colorectal cancer patients
43. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study
44. P31-7 Clinical outcomes of cerebral infarction associated with Trousseau’s syndrome in advanced pancreatic cancer patients
45. Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data.
46. Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment
47. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer
48. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
49. A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial.
50. Feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.